OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
August 02, 2014
Shrinking facility size, growth of biologics, and emerging market demand influence pharma investments.
August 01, 2014
Developments in chromatography column technology to deliver greater efficiency, speed and inertness benefit the drug development process from discovery to manufacturing and quality control.
Eric Langer of BioPlan Associates describes the development of biopharmaceutical outsourcing in Europe over the past 25 years.
Contract research, development, and manufacturing organizations invested in new facilities and technologies in 2014 for analytical testing, as well as small- and large-molecule drug development.
Contract service providers describe how quality by design has influenced a drug sponsor's expectations of suppliers.
Evolving clinical trial research services give biopharmaceutical companies options for full and functional services.
Representatives of contract service organizations that develop biologic-based drugs discussed technology trends such as high-throughput screening and single-use systems.
Experts from contract testing laboratories and service organizations shared their perceptions of analytical testing advances, and challenges still ahead.
Contract services ride high as funding floods bio/pharma.
Representatives of contract service organizations that specialize in parenteral drug development and manufacturing describe the evolving trends.